ES2263406T1 - Produccion de proteina capsida l1 y particulas tipo virus de papilomavirus humano hbv-11. - Google Patents
Produccion de proteina capsida l1 y particulas tipo virus de papilomavirus humano hbv-11.Info
- Publication number
- ES2263406T1 ES2263406T1 ES05075889T ES05075889T ES2263406T1 ES 2263406 T1 ES2263406 T1 ES 2263406T1 ES 05075889 T ES05075889 T ES 05075889T ES 05075889 T ES05075889 T ES 05075889T ES 2263406 T1 ES2263406 T1 ES 2263406T1
- Authority
- ES
- Spain
- Prior art keywords
- virus
- protein
- human papillomavirus
- particle
- capsomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Un polinucleótido que codifica una proteína cápsida L1 de HPV-11 en el que la región 3¿ no traducida del ARNm transcrito de la misma no contiene la secuencia AUUUA.
Claims (13)
1. Un polinucleótido que codifica una proteína
cápsida L1 de HPV-11 en el que la región 3' no
traducida del ARNm transcrito de la misma no contiene la secuencia
AUUUA.
2. Un polinucleótido que codifica una proteína
cápsida L1 de HPV-11 en el que la región 3' no
traducida del ARNm transcrito de la misma no contiene la secuencia
AUUUA dentro de las inmediaciones del codón de terminación de
L1.
3. Un polinucleótido según la reivindicación 1 o
la reivindicación 2 en las que dicho ARNm no contiene la secuencia
AUUUA dentro de los 30 nucleótidos del codón de terminación de la
secuencia de codificación de L1.
4. Un vector de expresión que consta de un
polinucleótido según la reivindicación 1 o la reivindi-
cación 2.
cación 2.
5. Un vector de expresión según la
reivindicación 4 el cual es un vector de expresión de
baculovirus.
6. Una célula hospedera que consta de un vector
de expresión según la reivindicación 4 ó 5.
7. Una célula huésped que consta del vector de
la reivindicación 5, en el que la célula huésped es una célula de
insecto.
8. Un método de producción de partículas o
capsómeros tipo virus de papilomavirus humano, método que comprende
el cultivo de la célula huésped según la reivindicación 6 o la
reivindicación 7 y la obtención de dicha partícula o capsómero tipo
virus del mismo.
9. Un método según la reivindicación 8, en la
que la proteína cápsida L1 es expresada a partir de una secuencia de
codificación de proteína L1, la cual produce una proteína o complejo
de proteínas que posee características inmunológicas y morfológicas
similares a aquellas del papilomavirus natural en el que dicha
partícula o capsómero es capaz de reconocer anticuerpos en suero
humano de personas que se conoce están infectadas con el virus
homólogo.
10. Un método según la reivindicación 8 ó 9 en
el que dicha partícula o capsómero tipo virus es purificado.
11. Un método de producción de una vacuna contra
el papilomavirus humano, el método comprende la obtención de una
partícula o capsómero tipo virus del papilomavirus humano según
cualquiera de las reivindicaciones de la 8 a la 10 y su combinación
con un adyuvante.
12. Un método de producción de una combinación
de partículas de tipo virus de papilomavirus humano, método que
comprende la producción de una partícula tipo virus del
papilomavirus humano que consta de una proteína cápsida L1 a partir
de HPV-11 según el método de cualquiera de las
reivindicaciones de la 8 a la 10 y la combinación con una o mas
partículas tipo virus que comprenden la proteína L1 de uno o mas
papilomavirus humanos diferentes.
13. Un método de producción de una vacuna
multivalente contra papilomavirus humanos, método que comprende la
obtención de una combinación de partículas tipo virus del
papilomavirus humano según la reivindicación 12 y su combinación con
\hbox{un adyuvante.} Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28517 | 1993-03-09 | ||
| US08/028,517 US8062642B1 (en) | 1993-03-09 | 1993-03-09 | Production of papillomavirus capsid protein and virus-like particles |
| US20730994A | 1994-03-07 | 1994-03-07 | |
| US207309 | 1994-03-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2263406T1 true ES2263406T1 (es) | 2006-12-16 |
| ES2263406T3 ES2263406T3 (es) | 2011-06-06 |
Family
ID=26703787
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05075889T Expired - Lifetime ES2263406T3 (es) | 1993-03-09 | 1994-03-08 | Producción de la proteína de capside l1 del papilomavirus humano hpv-11 y partículas de tipo virus. |
| ES05075369T Expired - Lifetime ES2263405T3 (es) | 1993-03-09 | 1994-03-08 | Producción de proteína de capside del papilomavirus humano y partículas de tipo virus. |
| ES94912186T Expired - Lifetime ES2242955T4 (es) | 1993-03-09 | 1994-03-08 | Produccion de la proteina de la capside del virus del papiloma humano y particulas de tipo viral. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05075369T Expired - Lifetime ES2263405T3 (es) | 1993-03-09 | 1994-03-08 | Producción de proteína de capside del papilomavirus humano y partículas de tipo virus. |
| ES94912186T Expired - Lifetime ES2242955T4 (es) | 1993-03-09 | 1994-03-08 | Produccion de la proteina de la capside del virus del papiloma humano y particulas de tipo viral. |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP1618888B1 (es) |
| JP (4) | JPH08507685A (es) |
| AT (3) | ATE296111T1 (es) |
| AU (3) | AU688759C (es) |
| CA (1) | CA2157932C (es) |
| DE (9) | DE05075369T1 (es) |
| DK (2) | DK1618888T3 (es) |
| ES (3) | ES2263406T3 (es) |
| FR (1) | FR11C0022I2 (es) |
| LU (3) | LU91313I2 (es) |
| NL (3) | NL300265I2 (es) |
| PT (2) | PT1618888E (es) |
| WO (1) | WO1994020137A1 (es) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1359156B1 (en) | 1991-07-19 | 2007-03-07 | University of Queensland | Vaccine against Human Papillomavirus (Type 18) |
| US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| AUPM358894A0 (en) * | 1994-01-31 | 1994-02-24 | Csl Limited | Modified papilloma virus l2 protein and vlps formed therefrom |
| DE4415743C2 (de) | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| US5888516A (en) * | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
| AUPM566794A0 (en) * | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
| DE122007000092I1 (de) * | 1994-10-07 | 2008-03-27 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
| AU2003235191B2 (en) * | 1994-10-07 | 2006-09-21 | Loyola University Of Chicago | Papilloma virus-like particles, fusion proteins as well as processes for their production |
| AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
| JP3958360B2 (ja) * | 1995-02-24 | 2007-08-15 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 |
| US5820870A (en) * | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
| IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
| US5840306A (en) * | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
| IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
| EP0863982B1 (en) * | 1995-11-15 | 2004-01-21 | Merck & Co., Inc. | Synthetic hpv11 virus-like particles |
| DE19543553B4 (de) * | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| US6908615B1 (en) | 1996-03-18 | 2005-06-21 | Merck & Co., Inc. | DNA encoding human papilloma virus type 18 |
| FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
| WO1998014564A1 (en) * | 1996-10-04 | 1998-04-09 | Merck & Co., Inc. | Synthetic hpv16 virus-like particles |
| CA2274474C (en) * | 1996-12-09 | 2008-07-22 | Steven Ludmerer | Synthetic hpv16 virus-like particles |
| US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
| US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
| US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
| US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
| DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| ES2357381T3 (es) * | 2000-09-18 | 2011-04-25 | Medimmune, Llc | Ensayo in vitro para medir la inmunogenia de una vacuna. |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| US7247433B2 (en) | 2001-08-13 | 2007-07-24 | University Of Rochester | Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| CA2531773A1 (en) | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional cytokines |
| WO2006113209A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| WO2006065166A1 (en) * | 2005-07-26 | 2006-06-22 | Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' | Protein l1 and protein e7 peptide-based composition for treating and preventing a human papillomaviral infection |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| US8778351B2 (en) | 2006-08-30 | 2014-07-15 | University Of Rochester | Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| EP3403667B1 (en) | 2006-09-26 | 2020-07-22 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| MX2009009342A (es) | 2007-03-02 | 2009-09-11 | Glaxosmithkline Biolog Sa | Metodo novedoso y composiciones. |
| BRPI0811016B1 (pt) | 2007-04-29 | 2021-09-21 | Xiamen Innovax Biotech Co., Ltd. | Proteína li truncada do papiloma vírus humano tipo 16 |
| EP2147926B1 (en) | 2007-04-29 | 2016-08-24 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated human papillomavirus type 18 l1 proteins |
| EP2154149B1 (en) | 2007-05-29 | 2019-07-10 | Xiamen University | A truncated l1 protein of human papillomavirus 6 |
| DK2910566T5 (en) | 2007-05-29 | 2016-11-07 | Univ Xiamen | Truncated L1 protein of human papillomavirus 11 |
| US20110091496A1 (en) * | 2008-01-19 | 2011-04-21 | Graham Barney S | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| AU2009336562B2 (en) | 2008-05-26 | 2012-12-20 | Cadila Healthcare Limited | Combined measles-human papilloma vaccine |
| GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| GB0820822D0 (en) | 2008-11-13 | 2008-12-24 | Inst Catala D Oncologia | Novel product and processes |
| EP2414512A1 (en) * | 2009-04-03 | 2012-02-08 | Deutsches Krebsforschungszentrum | Enhanced production of papillomavirus-like particles with a modified baculovirus expression system |
| SI2437753T1 (sl) | 2009-06-05 | 2016-12-30 | Infectious Disease Research Institute | Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| EP3242135B1 (en) | 2010-04-08 | 2020-07-01 | University of Pittsburgh - Of the Commonwealth System of Higher Education | B-cell antigen presenting cell assay |
| BR112013025799A2 (pt) | 2011-04-08 | 2016-12-20 | Immune Design Corp | método para induzir uma resposta imune em um sujeito, e, preparação |
| SI2811981T1 (sl) | 2012-02-07 | 2019-08-30 | Infectious Disease Research Institute | Izboljšanje adjuvantne formulacije, ki obsegajo TLR4 agoniste in postopki za uporabo le-teh |
| WO2013139744A1 (en) | 2012-03-18 | 2013-09-26 | Glaxosmithkline Biologicals S.A. | Method of vaccination against human papillomavirus |
| EP2850431B1 (en) | 2012-05-16 | 2018-04-18 | Immune Design Corp. | Vaccines for hsv-2 |
| EP3587455A1 (en) | 2012-10-23 | 2020-01-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| JP6426706B2 (ja) | 2013-04-18 | 2018-11-21 | イミューン デザイン コーポレイション | がん処置で使用するためのｇｌａ単剤療法 |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| BR112016015422A2 (pt) | 2013-12-31 | 2017-10-24 | Infectious Disease Res Inst | formulações de vacina de frasco único |
| BR112018017141A2 (pt) | 2016-02-22 | 2019-01-02 | Boehringer Ingelheim Vetmedica Gmbh | método para a imobilização de biomoléculas |
| CN109310773B (zh) | 2016-05-16 | 2022-04-26 | 传染病研究所 | 含有tlr激动剂的配制品和使用方法 |
| IL319503A (en) | 2016-05-16 | 2025-05-01 | Access To Advanced Health Inst | PEGylated liposomes and methods of use |
| BR112018074352B1 (pt) | 2016-06-01 | 2021-11-30 | Infectious Disease Research Institute | Partículas de nanoalume contendo um agente de dimensionamento |
| CN111315362A (zh) | 2017-06-15 | 2020-06-19 | 传染病研究所 | 纳米结构脂质载剂和稳定乳剂以及其用途 |
| KR102755593B1 (ko) | 2017-09-08 | 2025-01-20 | 액세스 투 어드밴스드 헬스 인스티튜트 | 사포닌을 포함하는 리포솜 제형 및 사용 방법 |
| EP3976092A1 (en) | 2019-05-25 | 2022-04-06 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
| US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
| JP2024506364A (ja) | 2021-02-11 | 2024-02-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｈｐｖワクチンの製造 |
| WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
| CN116375816B (zh) * | 2023-01-06 | 2023-09-05 | 北京康乐卫士生物技术股份有限公司 | 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956288A (en) * | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| NZ232913A (en) * | 1989-03-15 | 1992-08-26 | Gist Brocades Nv | Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations |
| EP1359156B1 (en) | 1991-07-19 | 2007-03-07 | University of Queensland | Vaccine against Human Papillomavirus (Type 18) |
-
1994
- 1994-03-08 EP EP05075369A patent/EP1618888B1/en not_active Expired - Lifetime
- 1994-03-08 PT PT05075369T patent/PT1618888E/pt unknown
- 1994-03-08 ES ES05075889T patent/ES2263406T3/es not_active Expired - Lifetime
- 1994-03-08 CA CA2157932A patent/CA2157932C/en not_active Expired - Lifetime
- 1994-03-08 DE DE05075369T patent/DE05075369T1/de active Pending
- 1994-03-08 DK DK05075369.8T patent/DK1618888T3/da active
- 1994-03-08 DE DE69434383T patent/DE69434383T2/de not_active Expired - Lifetime
- 1994-03-08 AT AT94912186T patent/ATE296111T1/de active
- 1994-03-08 EP EP05075889A patent/EP1588713B1/en not_active Expired - Lifetime
- 1994-03-08 PT PT94912186T patent/PT688227E/pt unknown
- 1994-03-08 AU AU64436/94A patent/AU688759C/en not_active Expired
- 1994-03-08 AT AT05075369T patent/ATE494005T1/de active
- 1994-03-08 DE DE69435332T patent/DE69435332D1/de not_active Expired - Lifetime
- 1994-03-08 ES ES05075369T patent/ES2263405T3/es not_active Expired - Lifetime
- 1994-03-08 DE DE122007000090C patent/DE122007000090I1/de active Pending
- 1994-03-08 EP EP94912186A patent/EP0688227B1/en not_active Expired - Lifetime
- 1994-03-08 DE DE05075889T patent/DE05075889T1/de active Pending
- 1994-03-08 WO PCT/US1994/002443 patent/WO1994020137A1/en not_active Ceased
- 1994-03-08 ES ES94912186T patent/ES2242955T4/es not_active Expired - Lifetime
- 1994-03-08 JP JP6520236A patent/JPH08507685A/ja not_active Withdrawn
- 1994-03-08 AT AT05075889T patent/ATE492289T1/de not_active IP Right Cessation
- 1994-03-08 DK DK94912186T patent/DK0688227T3/da active
- 1994-03-08 DE DE201112100018 patent/DE122011100018I1/de active Pending
- 1994-03-08 DE DE69435331T patent/DE69435331D1/de not_active Expired - Lifetime
- 1994-03-08 DE DE1994634383 patent/DE122007000014I1/de active Pending
- 1994-03-08 DE DE122007000089C patent/DE122007000089I1/de active Pending
-
2006
- 2006-10-11 JP JP2006277056A patent/JP4486075B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-21 NL NL300265C patent/NL300265I2/nl unknown
- 2007-02-21 LU LU91313C patent/LU91313I2/fr unknown
- 2007-03-07 AU AU2007201006A patent/AU2007201006B2/en not_active Expired
- 2007-03-07 AU AU2007201005A patent/AU2007201005B2/en not_active Expired
- 2007-12-14 NL NL300309C patent/NL300309I2/nl unknown
- 2007-12-14 LU LU91392C patent/LU91392I2/fr unknown
- 2007-12-14 NL NL300310C patent/NL300310I1/nl unknown
- 2007-12-14 LU LU91391C patent/LU91391I2/fr unknown
-
2010
- 2010-02-05 JP JP2010023691A patent/JP5386392B2/ja not_active Expired - Lifetime
- 2010-02-05 JP JP2010023690A patent/JP5306251B2/ja not_active Expired - Lifetime
-
2011
- 2011-07-04 FR FR11C0022C patent/FR11C0022I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2263406T1 (es) | Produccion de proteina capsida l1 y particulas tipo virus de papilomavirus humano hbv-11. | |
| DE69535018D1 (de) | Papillomavirus vakzine | |
| JP2012010713A (ja) | パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 | |
| NL300314I1 (nl) | Vaccin tegen humaan papillomavirus | |
| AR039005A1 (es) | Antigenos virales | |
| AR077396A2 (es) | EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS | |
| HUP9801334A2 (hu) | A 18-as típusú humán papillomavírust kódoló DNS | |
| ATE344052T1 (de) | Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt. | |
| TW200509964A (en) | VP1 of foot-and-mouth disease virus | |
| CO5580837A2 (es) | Vacuna dna que codifica al menos dos proteinas tempranas no estructurales de papilomavirus | |
| Sarode | O RCID |